Effects of Antrodia Cinnamomea on Spinocerebellar Ataxia Symptoms
Effects of Oral Administration of Antrodia Cinnamomea Products for Clinical Symptoms in Spinocerebellar Ataxia Patients
This study is testing whether a product made from Antrodia cinnamomea can help improve symptoms in people with spinocerebellar ataxia.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 30 Years to 70 Years |
| Sex | All |
| Sponsor | ALPS Biotech CO. LTD Industry-sponsored |
| Locations | 1 site (Taipei) |
| Trial ID | NCT06633003 on ClinicalTrials.gov |
What this trial studies
This study investigates the impact of Antrodia cinnamomea products on clinical symptoms in patients with spinocerebellar ataxia. It employs a randomized, double-blind, placebo-controlled crossover design to ensure robust results. The study aims to provide insights into potential advancements in treating neurodegenerative diseases. Participants will receive either the treatment or a placebo in a controlled manner to assess the efficacy of the intervention.
Who should consider this trial
Good fit: Ideal candidates are Chinese-speaking adults aged 30 to 70 diagnosed with spinocerebellar ataxia and a SARA score below 30.
Not a fit: Patients with severe systemic diseases or those who have recently used Antrodia cinnamomea products may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved management of symptoms for patients with spinocerebellar ataxia.
How similar studies have performed: While the specific use of Antrodia cinnamomea for spinocerebellar ataxia is novel, similar studies on neuroinflammatory diseases have shown promising results.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Adults aged 30 to 70 years, whose native language is Chinese. 2. Patients diagnosed with Spinocerebellar Ataxia. 3. Subjects with a score below 30 on the Scale for the Assessment and Rating of Ataxia (SARA scale). 4. Individuals who can read and write in Chinese and communicate in Chinese. 5. Agree to participate in the study. Exclusion Criteria: 1. Patients with severe systemic diseases, such as heart or respiratory failure, liver or kidney failure, severe brain injury, prolonged bed rest, or incurable malignancies. 2. Pregnant women and breastfeeding mothers. 3. Patients who have taken Antrodia cinnamomea products within the last 6 months prior to the trial. 4. Patients with other factors that prevent them from continuing to participate in this study.
Where this trial is running
Taipei
- National Taiwan University Cancer Center — Taipei, Taiwan (Recruiting)
Study contacts
- Principal investigator: MingChe Kuo — National Taiwan University
- Study coordinator: Yu Hsuan Chang
- Email: hsuan1989@alps.com.tw
- Phone: +886955551989
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.